Pulmatrix (PULM) Share-based Compensation (2014 - 2026)
Pulmatrix (PULM) posted Share-based Compensation of $3000.0 for Q1 2026, down 40.0% sequentially from $5000.0 in Q4 2025, and down 62.5% YoY from $8000.0 in Q1 2025.
Pulmatrix (PULM) Share-based Compensation (2014 - 2026) Analysis & Trends
Pulmatrix has reported Share-based Compensation for 13 years, with the latest figure at $3000.0 in Q1 2026.
- Quarterly Share-based Compensation fell 62.5% year-over-year to $3000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20000.0 (down 88.37% YoY) and the FY2025 annual result came in at $25000.0, down 93.09% from the prior year.
- Share-based Compensation eased to $3000.0 in Q1 2026 per PULM's latest filing, from $5000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $8.4 million in Q4 2023 and troughed at -$136000.0 in Q4 2024.
- A 5-year average of $624705.9 and a median of $198000.0 in 2024 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2024: Share-based Compensation jumped 2896.06% in 2023, then plunged 101.63% in 2024.
- Over 5 years, Share-based Compensation stood at $279000.0 in 2022, then surged by 2896.06% to $8.4 million in 2023, then slumped by 101.63% to -$136000.0 in 2024, then soared by 103.68% to $5000.0 in 2025, then sank by 40.0% to $3000.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $3000.0, $5000.0, and $6000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.01 Bn | 132.16 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.18 Bn | 55.04 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.55 Bn | 28.24 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.19 Bn | 26.36 Bn | - | - |
| 10 | Pulmatrix | 5.55 Mn | 5.55 Mn | - | 2,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2,000.00 |
| Jun 30, 2026 | 2,000.00 |
| Mar 31, 2026 | 3,000.00 |
| Mar 31, 2026 | 3,000.00 |
| Dec 31, 2025 | 5,000.00 |
| Dec 31, 2025 | 5,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Jun 30, 2025 | 6,000.00 |
| Jun 30, 2025 | 6,000.00 |
| Mar 31, 2025 | 8,000.00 |
| Mar 31, 2025 | 8,000.00 |
| Dec 31, 2024 | -136,000.00 |
| Dec 31, 2024 | -136,000.00 |
| Sep 30, 2024 | 197,000.00 |
| Sep 30, 2024 | 197,000.00 |
| Jun 30, 2024 | 103,000.00 |
| Jun 30, 2024 | 103,000.00 |
| Mar 31, 2024 | 198,000.00 |
| Mar 31, 2024 | 198,000.00 |